Home » Stocks » ARMP

Armata Pharmaceuticals, Inc. (ARMP)

Stock Price: $5.06 USD -0.52 (-9.32%)
Updated Mar 4, 2021 1:23 PM EST - Market open
Market Cap 116.55M
Revenue (ttm) 319,000
Net Income (ttm) -20.14M
Shares Out 18.39M
EPS (ttm) -1.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 4
Last Price $5.06
Previous Close $5.58
Change ($) -0.52
Change (%) -9.32%
Day's Open 5.45
Day's Range 5.06 - 5.61
Day's Volume 42,716
52-Week Range 2.52 - 10.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 1 month ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: INTC, TDY, AA, ATHA, FAST, FCEL, FRG, GRBK, RILY
PRNewsWire - 1 month ago

MARINA DEL REY, Calif., Jan. 27, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacte...

PRNewsWire - 2 months ago

MARINA DEL REY, Calif., Dec. 9, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacte...

PRNewsWire - 3 months ago

MARINA DEL REY, Calif., Nov. 12, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisel...

PRNewsWire - 4 months ago

MARINA DEL REY, Calif., Oct. 29, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacter...

PRNewsWire - 4 months ago

MARINA DEL REY, Calif., Oct. 26, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bact...

Zacks Investment Research - 4 months ago

Armata's (ARMP) AP-PA02 IND application gets clearance from the FDA to initiate a phase Ib/IIa study for the treatment of Pseudomonas aeruginosa infections.

PRNewsWire - 4 months ago

MARINA DEL REY, Calif., Oct. 15, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bact...

PRNewsWire - 5 months ago

MARINA DEL REY, Calif., Sept. 29, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bac...

PRNewsWire - 5 months ago

MARINA DEL REY, Calif., Sept. 11, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc.

PRNewsWire - 6 months ago

MARINA DEL REY, Calif., Aug. 13, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc.

About ARMP

Armata Pharmaceuticals, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating disease... [Read more...]

Industry
Biotechnology
CEO
Todd Patrick
Employees
33
Stock Exchange
NYSEAMERICAN
Ticker Symbol
ARMP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ARMP stock is "Buy." The 12-month stock price forecast is 7.25, which is an increase of 43.28% from the latest price.

Price Target
$7.25
(43.28% upside)
Analyst Consensus: Buy